Takeaway

• Pembrolizumab plus olaparib is safe and shows antitumor activity in previously treated patients with molecularly unselected, docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC).

Why this matters

• Few treatment options are available for patients whose disease progresses on both docetaxel and next-generation hormonal agents.

Study design

• Cohort A of the phase...